Skip to main content

Table 1 Participant characteristics at baseline (full analysis set)

From: Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

  Group 1
(N = 117)
Group 2
(N = 119)
Group 3
(N = 114)
Sex, n (%)
 Female 57 (48.7) 61 (51.3) 58 (50.9)
Age, years
 Mean (SD) 31.8 (7.7) 32.6 (7.3) 32.8 (7.6)
Racial origin
 White Caucasian 88 (75.2) 103 (86.6) 88 (77.2)
 Black or African American 21 (17.9) 14 (11.8) 19 (16.7)
 Other 8 (6.8) 2 (1.7) 7 (6.1)
Seropositivity status, n (%)a
 Dengue seropositive 9 (7.7) 9 (7.6) 8 (7.0)
 Yellow fever seropositiveb 59 (50.4) 61 (51.3) 6 (5.3)
 Flavivirus seropositive 63 (53.8) 65 (54.6) 11 (9.6)
  1. n number of participants with the specified characteristic, N total number of participants in the study group, SD standard deviation
  2. aParticipants were defined as dengue or YF seropositive if they had neutralising antibody titres > 10 1/dilution (for at least one serotype for dengue seropositivity); participants were considered FV seropositive if they were seropositive for dengue of YF, or both
  3. bParticipants were randomised to treatment groups with stratification on prior reported YF vaccination (in the 3 months to 10 years preceding first study vaccine dose), such that 50% of Group 1 and 2 participants and no participants in Group 3 had prior reported YF. Laboratory confirmation of YF seropositive status according to protocol revealed discrepancies between the YF PRNT50 assay and the reported YF vaccination history; the YF seropositive status of participants at baseline was thus re-calculated using YF PRNT80, a more stringent assay compared to YF PRNT50. Results based on PRNT80 are shown for YF and FV seropositive status